Jade Biosciences (NASDAQ:JBIO) Upgraded to Strong-Buy at HC Wainwright

Jade Biosciences (NASDAQ:JBIO) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

Several other brokerages have also recently issued reports on JBIO. Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Guggenheim boosted their target price on Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. Finally, BTIG Research began coverage on Jade Biosciences in a report on Thursday, October 9th. They set a “buy” rating and a $28.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.80.

Jade Biosciences Price Performance

JBIO stock opened at $13.19 on Wednesday. The company has a market cap of $650.40 million, a price-to-earnings ratio of -1.18 and a beta of 1.02. The company has a fifty day moving average price of $13.01 and a 200 day moving average price of $10.14. Jade Biosciences has a 12 month low of $6.57 and a 12 month high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09.

Institutional Trading of Jade Biosciences

A number of institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. acquired a new position in Jade Biosciences during the second quarter worth $17,703,000. Versant Venture Management LLC acquired a new position in shares of Jade Biosciences during the 2nd quarter worth $15,243,000. Soleus Capital Management L.P. acquired a new position in shares of Jade Biosciences during the 2nd quarter worth $7,959,000. Geode Capital Management LLC purchased a new position in shares of Jade Biosciences in the 2nd quarter valued at about $6,759,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Jade Biosciences in the second quarter valued at about $5,306,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.